More recently, liraglutide, a novel antidiabetic agent, was shown to influence SIRT1 expression in stroke patients, and this finding confirms that sirtuins are worthy of investigation to ameliorate treatment and prognosis of CKD patients, independently of the cause of primary kidney disease [128]. This evidence concerns the gene SIRT1 and chronic kidney disease.